Биология ва тиббиёт муаммолари 2024 №3 (154)

Тема статьи

ТЕРАПИЯ СИМПТОМОВ НИЖНИХ МОЧЕВЫХ ПУТЕЙ, ОБУСЛОВЛЕННЫХ ДОБРОКАЧЕСТВЕННОЙ ГИПЕРПЛАЗИЕЙ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ ПРЕПАРАТАМИ SERENOA REPENS: МИФ ИЛИ РЕАЛЬНОСТЬ? (390-397)

Авторы

Гафаров Рушен Рефатович

Учреждение

Самаркандский государственный медицинский университет, Республика Узбекистан, г. Самарканд

Аннотация

Обзорная статья посвящена фитотерапии симптомов нижних мочевых путей (СНМП), обусловленных доброкачественной гиперплазией предстательной железы (ДГПЖ), препаратами Serenoa repens (американской карликовой пальмы). Представлены сведения о различных лекарственных растениях, используемых при лечении ДГПЖ, многочисленных активных компонентах растительных экстрактов, механизмах их действия. Раскрыта роль различных препаратов Serenoa repens в лечении симптомов ДГПЖ, в зависимости от типа экстракта (гексановый, sCO2 (supercritical carbon dioxide - сверхкритический диоксид углерода) и этаноловый экстракты)) и его состава. В статье нашли от-ражение имеющиеся в современной литературе, довольно противоречивые, данные о клиническом использовании препаратов Serenoa repens, возможных побочных эффектах. Использованы в том числе и выводы значимых клинических испытаний, крупных систематических обзоров и мета-анализов.

Ключевые слова

фитотерапия, ДГПЖ, Serenoa repens, растительные экстракты, гексановый, sCO2, этаноловый.

Литературы

1. Miernik A., Gratzke C. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020;117:843-854. doi:10.3238/arztebl.2020.0843. 2. Plochocki A., King B. Medical Treatment of Benign Prostatic Hyperplasia. Urol Clin North Am. 2022;49(2):231-238. doi:10.1016/J.UCL.2021.12.003. 3. Shvero A., Calio B., Humphreys M.R., Das A.K. HoLEP: the new gold standard for surgical treatment of benign prostatic hyperplasia. Can J Urol. 2021;28(S2):6-10. PMID: 34453422. 4. Shodmonova Z.R., Gafarov R.R., Allazov S.A., Giyasov S.I. Phosphodesterase type 5 inhibitors – clinical efficiency and role in therapy for erectile dysfunction. Urologiia. 2021;2:135-140. doi:10.18565/urology.2021.2.135-140 (In Russian). 5. Giyasov Sh.I., Gafarov R.R., Shodmonova Z.R., Mukhtarov Sh.T., Akilov F.A. The role of systematization of postoperative complications in assessing the efficiency and safety of surgical methods for the treatment of benign prostatic hyperplasia. Urologiia. 2022;3:83-91. doi:10.18565/urology.2022.3.83-91 (In Russian). 6. EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2023. 7. Lowe F.C., Ku J.C. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology. 1996;48(1):12-20. doi: 10.1016/s0090-4295(96)00077-5. 8. Antoniou V., Gauhar V., Modi S., Somani B.K. Role of phytotherapy in the management of BPH: a summary of the literature. J Clin Med. 2023;12(5):1899. doi:10.3390/jcm12051899. 9. Li S., Lu A., Wang Y. Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches. Complement Ther Med. 2010;18(1):21-27. doi:10.1016/j.ctim.2009.10.002. 10. Kato S., Hayashi S., Kitahara Y. et al. Saireito (TJ-114), a Japanese traditional herbal medicine, reduces 5-fluorouracil-induced intestinal mucositis in mice by inhibiting cytokine-mediated apoptosis in intestinal crypt cells. PLoS One. 2015;10(1):e0116213. doi:10.1371/journal.pone.0116213. 11. Liao S. The medicinal action of androgens and green tea epigallocatechin gallate. Hong Kong Med J. 2001;7(4):369-74. PMID: 11773671. 12. Kane C.J., Raheem O.A., Bent S., Avins A.L. What do i tell patients about saw palmetto for benign prostatic hyperplasia? Urologic Clinics of North America. 2011;38(3):261-277. doi:10.1016/j.ucl.2011.04.005. 13. Noguchi M., Kakuma T., Tomiyasu K. et al. Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: A double-blind, placebo-controlled randomized and dose-ranging study. Asian J Androl. 2008;10(4):651-658. doi:10.1111/j.1745-7262.2008.00336.x. 14. Kwon Y. Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia. Food Sci Biotechnol. 2019;28(6):1599-1606. doi:10.1007/s10068-019-00605-9. 15. Madersbacher S., Berger I., Ponholzer A., Marszalek M. Plant extracts: sense or nonsense? Curr Opin Urol. 2008;18(1):16-20. doi: 10.1097/MOU.0b013e3282f0d5c8. 16. Bennett B., Hicklin J. Uses of Saw Palmetto (Serenoa repens, arecaceae) in Florida. Econ Bot. 1998;52:381-393. doi:10.1007/BF02862068. 17. Russo A., Capogrosso P., La Croce G. et al. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. Expert Opin Drug Saf. 2016;15(12):1661-1670. doi:10.1080/14740338.2016.1190830. 18. Booker A., Suter A., Krnjic A. et al. A phytochemical comparison of saw palmetto products using gas chromatography and 1H nuclear magnetic resonance spectroscopy metabolomic profiling. Journal of Pharmacy and Pharmacology. 2014;66(6):811-822. doi:10.1111/jphp.12198. 19. Vlietinck A. European Union herbal monograph on **Serenoa repens** (W. Bartram) Small, fructus EMA/HMPC/280079, 5 p. Published online August 2016. 20. Geavlete P., Multescu R., Geavlete B. Serenoa repens extract in the treatment of benign prostatic hyperplasia. Ther Adv Urol. 2011;3(4):193-198. doi:10.1177/1756287211418725. 21. Marti G., Joulia P., Amiel A. et al. Comparison of the phytochemical composition of serenoa repens extracts by a multiplexed metabolomic approach. Molecules. 2019;24(12):2208. doi:10.3390/molecules24122208. 22. Habib F.K., Wyllie M.G. Not all brands are created equal: A comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis. 2004;7(3):195-200. doi:10.1038/sj.pcan.4500746. 23. Scaglione F., Lucini V., Pannacci M., Caronno A., Leone C. Comparison of the potency of different brands of Serenoa repens extract on 5α-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology. 2008;82(4):270-275. doi:10.1159/000161128. 24. Vela-Navarrete R., Alcaraz A., Rodríguez-Antolín A. et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018;122(6):1049-1065. doi:10.1111/bju.14362. 25. Bent S., Kane C., Shinohara K., Neuhaus J., Hudes E.S., Goldberg H., Avins A.L. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354(6):557-66. doi: 10.1056/NEJMoa053085. 26. Barry M.J., Meleth S., Lee J.Y. et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: A randomized trial. JAMA. 2011;306(12):1344-1351. doi:10.1001/jama.2011.1364. 27. Debruyne F., Koch G., Boyle P. et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol. 2002;41(5):497-506; discussion 506-7. PMID: 12074791. 28. Latil A., Pétrissans M.T., Rouquet J., Robert G., De La Taille A. Effects of hexanic extract of serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75(16):1857-1867. doi:10.1002/pros.23059. 29. Alcaraz A., Carballido-Rodríguez J., Unda-Urzaiz M. et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment-the QUALIPROST study. Int Urol Nephrol. 2016;48(5):645-656. doi:10.1007/s11255-015-1206-7. 30. de la Taille A., Bardin L., Castagné C. et al. Alpha-blockers or phytotherapy as first-line treatment of LUTS/BPH in general medicine: The PERSAT non-interventional study. Progres en Urologie. 2020;30(10):522-531. doi:10.1016/j.purol.2020.07.001. 31. Vinarov A.Z., Spivak L.G., Platonova D.V., Rapoport L.M., Korolev D.O. 15 years’ survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression. Urologia Journal. 2019;86(1):17-22. doi:10.1177/0391560318772466. 32. Agbabiaka T.B., Pittler M.H., Wider B., Ernst E. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf. 2009;32(8):637-47. doi: 10.2165/00002018-200932080-00003. 33. Tacklind J., MacDonald R., Rutks I., Wilt T.J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews. 2009;(2). doi:10.1002/14651858.CD001423.pub2. 34. Franco J.V., Trivisonno L., Sgarbossa N.J. et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database Syst Rev. 2023;6:CD001423. doi:10.1002/14651858.CD001423.pub4.